IceCure Medical (Nasdaq:ICCM) disclosed today its reception of an intention to grant notice from the European Patent Office. The notice endorses the company’s innovation, the Cryogenic System Connector, which recently received a patent in the United States as well. Based in Caesarea, Israel, IceCure designed this connector to complement their XSense cryoablation system. This connector is crafted to enhance safety and preserve the cryogen’s stability during the cryoablation procedure.
IceCure’s XSense system is engineered to eradicate tissue through the application of extremely low temperatures, targeting areas such as fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions, and warts. The XSense system achieved FDA clearance in July 2024 for all applications already approved under the company’s ProSense system, encompassing minimally invasive cryoablation in areas like general surgery, dermatology, neurology (including cryoanalgesia), as well as thoracic surgery, ENT, gynecology, oncology, proctology, and urology.
Utilizing liquid nitrogen, the system generates extensive destructive zones to maximize tumor elimination. IceCure claims the system accelerates patient recovery while minimizing pain and the risks associated with surgery. It also features a user-friendly design that supports rapid, transportable procedures suitable for office-based environments.
“We are witnessing significant momentum in expanding our intellectual property portfolio, further solidifying our global leadership in cryoablation. Europe represents a significant market for us, with several key distributors offering ProSense® and multiple new and ongoing independent clinical studies spearheaded by doctors using our cryoablation technology for various applications,” remarked Eyal Shamir, CEO of IceCure.